Erasca (ERAS) said Thursday that it has entered into a clinical trial collaboration and supply agreement with Tango Therapeutics (TNGX) to evaluate its experimental drug, ERAS-0015, in combination with Tango's vopimetostat.

The company said the agreement would support phase 1/2 trial, which will target patients with a type of pancreatic cancer or non-small cell lung cancer.

Erasca said that, as part of the agreement, it will supply ERAS-0015 free of charge, while Tango will serve as the trial sponsor.

Both companies will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive, Erasca said.